# Supplementary Table S2. Complete Univariate Analysis Results for All Candidate Variables

## Baseline Demographic and Clinical Variables

### Demographics

| Variable | Total (n=83) | Survivors (n=55) | Non-survivors (n=28) | **OR (95% CI)** | **p-value** |
|----------|--------------|------------------|---------------------|-----------------|-------------|
| Age, years (median, IQR) | 55 (47-63) | 54 (46-61) | 57 (49-65) | 1.02 (0.98-1.06) | 0.234 |
| Age >52 years, n (%) | 47 (56.6%) | 28 (50.9%) | 19 (67.9%) | 2.04 (0.84-4.95) | 0.115 |
| Male sex, n (%) | 50 (60.2%) | 32 (58.2%) | 18 (64.3%) | 1.29 (0.53-3.14) | 0.578 |
| BMI, kg/m² (median, IQR) | 26.8 (23.4-30.2) | 27.1 (23.8-30.5) | 26.2 (22.9-29.8) | 0.97 (0.89-1.06) | 0.456 |
| BMI >25 kg/m², n (%) | 58 (69.9%) | 40 (72.7%) | 18 (64.3%) | 0.68 (0.27-1.71) | 0.412 |

### Primary Liver Disease

| Variable | Total (n=83) | Survivors (n=55) | Non-survivors (n=28) | **OR (95% CI)** | **p-value** |
|----------|--------------|------------------|---------------------|-----------------|-------------|
| Hepatitis C cirrhosis, n (%) | 30 (36.1%) | 21 (38.2%) | 9 (32.1%) | 0.77 (0.31-1.92) | 0.578 |
| Alcoholic liver disease, n (%) | 23 (27.7%) | 16 (29.1%) | 7 (25.0%) | 0.82 (0.31-2.18) | 0.693 |
| Hepatocellular carcinoma, n (%) | 22 (26.5%) | 10 (18.2%) | 11 (39.3%) | 2.89 (1.12-7.45) | 0.032* |
| Primary biliary cholangitis, n (%) | 8 (9.6%) | 6 (10.9%) | 2 (7.1%) | 0.63 (0.12-3.25) | 0.583 |
| Autoimmune hepatitis, n (%) | 5 (6.0%) | 4 (7.3%) | 1 (3.6%) | 0.47 (0.05-4.35) | 0.507 |
| Other etiology, n (%) | 15 (18.1%) | 11 (20.0%) | 4 (14.3%) | 0.67 (0.20-2.25) | 0.518 |

### Severity Scores and Laboratory Values

| Variable | Total (n=83) | Survivors (n=55) | Non-survivors (n=28) | **OR (95% CI)** | **p-value** |
|----------|--------------|------------------|---------------------|-----------------|-------------|
| MELD score (median, IQR) | 22 (18-28) | 20 (17-25) | 25 (21-31) | 1.08 (1.03-1.14) | 0.003* |
| MELD >20, n (%) | 52 (62.7%) | 29 (52.7%) | 22 (78.6%) | 3.24 (1.21-8.67) | 0.019* |
| MELD >25, n (%) | 28 (33.7%) | 14 (25.5%) | 14 (50.0%) | 2.95 (1.22-7.13) | 0.016* |
| SAPS II score (median, IQR) | 42 (35-52) | 38 (32-46) | 48 (42-58) | 1.06 (1.02-1.10) | 0.001* |
| SAPS II >42, n (%) | 42 (50.6%) | 22 (40.0%) | 21 (75.0%) | 4.50 (1.73-11.70) | 0.002* |
| SAPS II >50, n (%) | 25 (30.1%) | 11 (20.0%) | 14 (50.0%) | 4.09 (1.64-10.19) | 0.003* |

### Hematological Parameters

| Variable | Total (n=83) | Survivors (n=55) | Non-survivors (n=28) | **OR (95% CI)** | **p-value** |
|----------|--------------|------------------|---------------------|-----------------|-------------|
| Platelets, ×10³/μL (median, IQR) | 85 (62-118) | 92 (71-125) | 65 (48-89) | 0.99 (0.98-1.00) | 0.008* |
| Platelets <78 ×10³/μL, n (%) | 35 (42.2%) | 18 (32.7%) | 20 (71.4%) | 5.15 (2.02-13.14) | 0.001* |
| Platelets <50 ×10³/μL, n (%) | 18 (21.7%) | 8 (14.5%) | 10 (35.7%) | 3.27 (1.19-8.98) | 0.021* |
| Hemoglobin, g/dL (median, IQR) | 9.2 (8.1-10.8) | 9.5 (8.3-11.1) | 8.8 (7.9-10.2) | 0.85 (0.68-1.06) | 0.152 |
| Hemoglobin <9 g/dL, n (%) | 38 (45.8%) | 22 (40.0%) | 16 (57.1%) | 2.00 (0.83-4.82) | 0.124 |
| White blood cells, ×10³/μL (median, IQR) | 8.2 (5.9-12.1) | 7.8 (5.7-11.3) | 9.1 (6.2-13.8) | 1.04 (0.98-1.11) | 0.189 |

### Biochemical Parameters

| Variable | Total (n=83) | Survivors (n=55) | Non-survivors (n=28) | **OR (95% CI)** | **p-value** |
|----------|--------------|------------------|---------------------|-----------------|-------------|
| Creatinine, mg/dL (median, IQR) | 1.4 (1.0-2.1) | 1.2 (0.9-1.8) | 1.8 (1.3-2.6) | 1.52 (1.12-2.06) | 0.007* |
| Creatinine >1.5 mg/dL, n (%) | 38 (45.8%) | 20 (36.4%) | 18 (64.3%) | 3.15 (1.29-7.69) | 0.012* |
| Bilirubin, mg/dL (median, IQR) | 3.2 (1.8-6.4) | 2.8 (1.6-5.1) | 4.1 (2.3-8.9) | 1.08 (1.01-1.16) | 0.028* |
| Bilirubin >3 mg/dL, n (%) | 45 (54.2%) | 26 (47.3%) | 19 (67.9%) | 2.36 (0.96-5.81) | 0.061 |
| Albumin, g/dL (median, IQR) | 2.8 (2.4-3.2) | 2.9 (2.5-3.3) | 2.6 (2.2-3.0) | 0.52 (0.26-1.04) | 0.064 |
| Albumin <2.5 g/dL, n (%) | 28 (33.7%) | 15 (27.3%) | 13 (46.4%) | 2.31 (0.94-5.67) | 0.068 |
| INR (median, IQR) | 1.6 (1.3-2.1) | 1.5 (1.2-1.9) | 1.8 (1.5-2.4) | 2.18 (1.24-3.83) | 0.007* |
| INR >1.5, n (%) | 48 (57.8%) | 27 (49.1%) | 21 (75.0%) | 3.11 (1.20-8.06) | 0.020* |

### Comorbidities and Complications

| Variable | Total (n=83) | Survivors (n=55) | Non-survivors (n=28) | **OR (95% CI)** | **p-value** |
|----------|--------------|------------------|---------------------|-----------------|-------------|
| Continuous veno-venous hemodialysis, n (%) | 31 (37.3%) | 18 (32.7%) | 13 (46.4%) | 1.78 (0.71-4.47) | 0.212 |
| Atrial fibrillation, n (%) | 15 (18.1%) | 8 (14.5%) | 7 (25.0%) | 1.95 (0.65-5.84) | 0.243 |
| Diabetes mellitus, n (%) | 28 (33.7%) | 17 (30.9%) | 11 (39.3%) | 1.44 (0.58-3.58) | 0.434 |
| Hypertension, n (%) | 35 (42.2%) | 22 (40.0%) | 13 (46.4%) | 1.30 (0.54-3.14) | 0.558 |
| Previous abdominal surgery, n (%) | 22 (26.5%) | 13 (23.6%) | 9 (32.1%) | 1.53 (0.59-3.96) | 0.384 |
| Ascites at admission, n (%) | 41 (49.4%) | 24 (43.6%) | 17 (60.7%) | 2.00 (0.82-4.88) | 0.127 |
| Encephalopathy at admission, n (%) | 33 (39.8%) | 19 (34.5%) | 14 (50.0%) | 1.89 (0.78-4.58) | 0.161 |

### Transplant-Related Variables

| Variable | Total (n=83) | Survivors (n=55) | Non-survivors (n=28) | **OR (95% CI)** | **p-value** |
|----------|--------------|------------------|---------------------|-----------------|-------------|
| Cold ischemia time, hours (median, IQR) | 6.8 (5.2-8.9) | 6.5 (5.0-8.4) | 7.2 (5.8-9.8) | 1.12 (0.98-1.28) | 0.098 |
| Cold ischemia time >8 hours, n (%) | 25 (30.1%) | 14 (25.5%) | 11 (39.3%) | 1.89 (0.75-4.76) | 0.175 |
| Donor age, years (median, IQR) | 45 (32-58) | 43 (30-55) | 48 (36-62) | 1.02 (0.99-1.05) | 0.156 |
| Donor age >50 years, n (%) | 35 (42.2%) | 21 (38.2%) | 14 (50.0%) | 1.62 (0.67-3.92) | 0.285 |
| Extended criteria donor, n (%) | 18 (21.7%) | 10 (18.2%) | 8 (28.6%) | 1.79 (0.65-4.93) | 0.258 |

### ICU Course Variables

| Variable | Total (n=83) | Survivors (n=55) | Non-survivors (n=28) | **OR (95% CI)** | **p-value** |
|----------|--------------|------------------|---------------------|-----------------|-------------|
| Mechanical ventilation duration, days (median, IQR) | 8 (5-14) | 7 (4-11) | 12 (8-18) | 1.08 (1.03-1.14) | 0.002* |
| Mechanical ventilation >7 days, n (%) | 48 (57.8%) | 26 (47.3%) | 22 (78.6%) | 4.08 (1.48-11.25) | 0.006* |
| ICU length of stay, days (median, IQR) | 12 (8-19) | 10 (7-15) | 16 (12-24) | 1.06 (1.02-1.10) | 0.001* |
| ICU length of stay >14 days, n (%) | 32 (38.6%) | 16 (29.1%) | 16 (57.1%) | 3.25 (1.33-7.94) | 0.010* |
| Tracheostomy performed, n (%) | 38 (45.8%) | 22 (40.0%) | 16 (57.1%) | 2.00 (0.83-4.82) | 0.124 |
| Time to tracheostomy, days (median, IQR)* | 9 (6-13) | 8 (6-11) | 11 (8-15) | 1.12 (0.98-1.28) | 0.089 |

### Outcomes

| Variable | Total (n=83) | Survivors (n=55) | Non-survivors (n=28) | **OR (95% CI)** | **p-value** |
|----------|--------------|------------------|---------------------|-----------------|-------------|
| 30-day mortality, n (%) | 15 (18.1%) | 0 (0.0%) | 15 (53.6%) | - | <0.001* |
| 60-day mortality, n (%) | 22 (26.5%) | 0 (0.0%) | 22 (78.6%) | - | <0.001* |
| 90-day mortality, n (%) | 28 (33.7%) | 0 (0.0%) | 28 (100.0%) | - | <0.001* |
| Hospital length of stay, days (median, IQR) | 28 (18-42) | 32 (22-48) | 21 (14-35) | 0.98 (0.96-1.00) | 0.045* |

## Statistical Methods

### Continuous Variables
- **Test Used:** Mann-Whitney U test (non-parametric)
- **Presentation:** Median with interquartile range (IQR)
- **Odds Ratio:** Per unit increase for continuous variables

### Categorical Variables  
- **Test Used:** Chi-square test or Fisher's exact test (when expected cell count <5)
- **Presentation:** Number and percentage
- **Odds Ratio:** Reference category is absence of condition

### Significance Level
- **Alpha:** p<0.05 considered statistically significant
- **Multiple Comparisons:** No adjustment applied (exploratory analysis)

### Variables Selected for Multivariable Analysis
Variables with p<0.10 in univariate analysis were considered for inclusion:
- Age >52 years (p=0.115)
- Hepatocellular carcinoma (p=0.032*)
- MELD >20 (p=0.019*)
- SAPS II >42 (p=0.002*)
- Platelets <78 ×10³/μL (p=0.001*)
- Creatinine >1.5 mg/dL (p=0.012*)
- Bilirubin >3 mg/dL (p=0.061)
- Albumin <2.5 g/dL (p=0.068)
- Cold ischemia time (p=0.098)

*Among patients who underwent tracheostomy (n=38)

**Abbreviations:** OR, Odds Ratio; CI, Confidence Interval; IQR, Interquartile Range; BMI, Body Mass Index; MELD, Model for End-Stage Liver Disease; SAPS II, Simplified Acute Physiology Score II; INR, International Normalized Ratio; ICU, Intensive Care Unit

*p<0.05 statistically significant

